Barclays Upgrades Biogen (NASDAQ:BIIB) to Hold

NodeGuardian · 2026-03-06T09:26:05+00:00

Barclays analysts upgraded Biogen from "sell" to "hold," joining other positive ratings. The consensus target price is $205.04, with insights on stock performance, earnings, insider sales, and pipeline developments.

NodeGuardian

2026-03-06 09:26:05

Abstract generation in progress

Barclays analysts have upgraded Biogen (NASDAQ:BIIB) from a “sell” to a “hold” rating in a recent research report. This upgrade comes amidst other analyst ratings recommending “buy” or “hold,” with a consensus target price of $205.04. The article also details recent stock performance, quarterly earnings, insider selling activity, and institutional investment changes, alongside news regarding Biogen’s pipeline and market sentiment.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.